Galaxy and GC Green Cross Begin Joint Development of Antibody Drugs for Autoimmune Diseases

"Combining AI Antibody Design Technology with New Drug Development Expertise"
Aiming to Discover Non-Clinical Candidate Substances

Artificial intelligence (AI) drug development company Galaxy is partnering with GC Green Cross to jointly develop antibody-based new drugs for the treatment of autoimmune diseases.

Galaxy, GC Green Cross company logo images. Galaxy GC Green Cross

On the 21st, Galaxy announced that it will pursue an initial joint research project to discover non-clinical candidate substances by combining its AI-based antibody design technology with GC Green Cross's pharmaceutical research and development capabilities.

In this collaboration, Galaxy will use its de novo antibody design technology to develop novel antibody candidates optimized for autoimmune disease target proteins. GC Green Cross will experimentally verify the biological activity and development potential of the designed antibodies. Both companies plan to secure new drug candidates through a process of evaluating, selecting, and optimizing antibody candidates generated by AI.

Galaxy has been expanding the application of its AI antibody design technology through joint drug development collaborations with domestic and global pharmaceutical companies such as Boehringer Ingelheim, Celltrion, LG Chem, and HanAll Biopharma. The latest agreement with GC Green Cross represents a further expansion into the field of autoimmune diseases.

Tae-yong Park, Vice President of Galaxy, stated, "Through collaborations with various pharmaceutical companies, we are rapidly accumulating real-world examples of AI drug design technology applied to actual development. With this collaboration, we aim to quickly secure differentiated autoimmune disease therapies utilizing AI." Jae-wook Jeong, Head of R&D at GC Green Cross, said, "Autoimmune diseases still represent an area with significant unmet needs. We will verify the potential of AI-based antibody design technology and work toward developing differentiated therapies."

This content was produced with the assistance of AI translation services.